0001104659-21-076496.txt : 20210603 0001104659-21-076496.hdr.sgml : 20210603 20210603175536 ACCESSION NUMBER: 0001104659-21-076496 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210601 FILED AS OF DATE: 20210603 DATE AS OF CHANGE: 20210603 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Graham G. Walmsley CENTRAL INDEX KEY: 0001777517 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38944 FILM NUMBER: 21993897 BUSINESS ADDRESS: STREET 1: ONE SANSOME STREET, SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 BUSINESS PHONE: 415-801-8100 MAIL ADDRESS: STREET 1: ONE SANSOME STREET, SUITE 3630 CITY: SAN FRANCISCO STATE: CA ZIP: 94104 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akero Therapeutics, Inc. CENTRAL INDEX KEY: 0001744659 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-487-6488 MAIL ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 tm2118278-2_4seq1.xml OWNERSHIP DOCUMENT X0306 4 2021-06-01 0 0001744659 Akero Therapeutics, Inc. AKRO 0001777517 Graham G. Walmsley C/O AKERO THERAPEUTICS, INC., 601 GATEWAY BLVD, SUITE 350 SOUTH SAN FRANCISCO, CA 94080 1 0 0 0 Stock Option (Right to Buy) 26.32 2021-06-01 4 A 0 13000 0 A 2031-05-31 Common Stock 13000 13000 D Stock Option (Right to Buy) 26.32 2021-06-01 5 G 0 E 13000 0 D 2031-05-31 Common Stock 13000 0 D Stock Option (Right to Buy) 26.32 2031-05-31 Common Stock 13000 13000 I See footnote Stock Option (Right to Buy) 19.97 2021-06-01 5 G 0 E 23832 0 D 2029-11-07 Common Stock 23832 0 D Stock Option (Right to Buy) 19.97 2029-11-07 Common Stock 23832 23832 I See footnote Stock Option (Right to Buy) 25.2 2021-06-01 5 G 0 E 13000 0 D 2030-05-31 Common Stock 13000 0 D Stock Option (Right to Buy) 25.2 2030-05-31 Common Stock 13000 13000 I See footnote This option shall vest in full upon the earlier of (i) June 1, 2022 or (ii) the date of the next annual meeting, all vesting shall cease if the director resigns from the Board or otherwise ceases to service as a director. On June 1, 2021, the reporting person transferred 13,000 options to an entity of which the reporting person is the sole member. This option shall vest and become exercisable in 36 equal monthly installments, commencing on November 8, 2019. On June 1, 2021, the reporting person transferred 23,832 options to an entity of which the reporting person is the sole member. This option is fully vested. On June 1, 2021, the reporting person transferred 13,000 options to an entity of which the reporting person is the sole member. /s/ Jonathan Young, attorney-in-fact 2021-06-03